Home > Articles by: Salateen Philip

Author: Salateen Philip

24. Recall Alert – Veterinary Drug Products declared Substandard by DTL Punjab

Salateen Philip Recall Alerts

Recall Alert

Download

VETERINARY DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

DRAP Alert NoNo I/S/04-26-24
Action Date14 April, 2026.
Target Audience·         National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
·         Healthcare Professionals-Veterinarians
·         Farmers/consumers
Problem / Issue Provincial Drug Testing Laboratories, Punjab informed that the sample of below mentioned Veterinary Drug products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#Product DetailsBatchManufacturer detailsRemarks
1Injection MAC ROLD 1% 10ml Ivermectin: 10 mg/ml (Reg # 106804)YI-152M/s Haarolds Pharmaceuticals (Pvt.) Ltd. Plot No.60-64/C, Small Industrial Estate, Bhimber, AJK. (DML # 000921)The sample is declared as “misbranded” as per Section 3(s)(vi) of The Drugs Act 1976 and “SUB-STANDARD” on the basis of Assay Test and Test for Related Substances.
Risk Statement:The use of this substandard and misbranded veterinary ivermectin injection may lead to ineffective parasite control, development of drug resistance, and potential toxicity in animals due to incorrect potency and presence of impurities. This can adversely affect animal health, productivity, and may pose indirect risks to public health through the food chain. Livestock animals (cattle, sheep, goats) treated for parasitic infections, particularly in commercial farming settings, and farmers relying on effective deworming for animal health and productivity.
Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

– All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

–Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk.

–Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for VeterinarianThis alert applies strictly to the specific batches listed above and does not apply to other batches of the same products. Veterinarians are therefore advised not to prescribe, administer, or stock these identified batches under any circumstances. In case any of the above-mentioned batches have already been administered, treated animals should be closely monitored for possible signs of infection, treatment failure, or adverse reactions, and appropriate supportive care must be provided. Any suspected adverse events or quality-related problems linked to these batches should be reported immediately to DRAP’s Pharmacovigilance Centre and to the Provincial Livestock & Dairy Development Departments. Practitioners are further advised to ensure that only alternative registered and quality-assured batches are used in veterinary practice.
Advice for Farmers and Livestock OwnersFarmers and livestock owners are advised to immediately stop using the affected batch and isolate all remaining stock. Closely monitor treated animals for fever, swelling at the injection site, reduced appetite, or any sudden illness, and consult a veterinarian if such symptoms appear. Until animals are clinically stable, avoid selling or using milk or meat from visibly unwell animals. The affected product should be returned to the supplier or distributor according to recall instructions. Farmers are further advised to maintain proper records of batch numbers, treatment dates, and suppliers for traceability, and to ensure that only sterile, approved veterinary injections are used and stored under recommended conditions.

    23. Recall Alert – Class II – Drug Products – Provincial reports

    Salateen Philip Recall Alerts

    Recall Alert

    Download
    DRUG PRODUCT DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES, PUNJAB.
    DRAP Alert NoNo I/S/03-26-23
    Action Date14 April, 2026.
    Target Audience– National Regulatory Field Force.
    – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
    – General Public
    Problem / Issue Drug Testing Laboratories informed that the samples of below mentioned drug products have been declared as ‘Substandard ’.

    Therapeutic Goods (s) Affected: –

    S#Product NameBatchManufacturersRemarks
    1.Tablet Nitras Each sustained release tablet contains: Glycerin Trinitrate …. 2.6 mg (Reg # 056007)24L069M/s Caraway Pharmaceuticals. Plot No. 12 Street No. N-3 National Industrial Zone (RCCI) Rawat. (DML # 000629)The Sample is declared as “sub-standard” on the basis of Assay & Dissolution Test.
    2.Tablet Kadin 2 mg Each Tablet Contains: Tizanidine (as Hydrochloride) …… 2mg (Reg # 033347)569M/s FYNK Pharmaceuticals.  19-Km Ferozepur Road G.T. Road Kala shah Kaku Lahore. (DML # 000494)The sample is declared as “adulterated” as per section 3 (a) (iv) of The Drugs Act 1976 (Paracetamol identified).
    3.Tablet Loratamin Each Film Coated Tablet Contains: Loratadine USP 10mg (Reg # 062647)24M/s Murfy Pharmaceuticals (Pvt) Ltd.  8-Km Raiwind Road Lahore. (DML # 000543)The above sample is adulterated as per The Drugs Act 1976, 3 (a)(iv) on the basis of Identification and Quantification of Paracetamol.
    4.ACEFYL COUGH SYRUP Each 5mL contains: Acefylline Piperazine….45mg, Diphenhydramine HCl…8mg (Reg # 023394)ACH479M/s NABIQASIM INDUSTRIES (PVT.) LTD., 17/24, Korangi Industrial Area, Karachi.  (DML # 000105).The above sample is ADULTERATED as per The Drugs Act 1976, 3 {a (i)} (The one unit of sample contains a glass piece in it).
    5.Tablet ORTIZIN/10mg Each film coated tablet contains. Cetirizine dihydrochloride U.S.P 10 mg (Reg #  025405)25F135M/s Obsons Pharmaceuticals.  209-S Industrial Estate Kot Lakhpat Lahore. (DML # 000416)The sample is declared as “SUB-STANDARD” on the basis of Assay Test and Test for Impurities (Organic Impurities).
    Risk Statement:The use of these substandard and adulterated oral products may result in reduced therapeutic efficacy, unexpected adverse drug reactions, and serious safety concerns due to incorrect active ingredients, contamination (including glass particles), and failure to meet quality standards. This may lead to inadequate disease control, allergic reactions, or physical injury to patients. Patients using these medicines for cardiac conditions, allergies, muscle spasm, and cough particularly children, elderly individuals, and those with chronic illnesses who rely on consistent and safe oral medication therapy.
    Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

    – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

    –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk.

    –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
    Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

    -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the     Adverse Event Reporting Form or online through this link.

    -Please click here for further information on problem reporting to DRAP.
    Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

    -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

      22. Recall Alert – Drug Products declared substandard by Provincial laboratories.

      Salateen Philip Recall Alerts

      Recall Alert

      Download
      DRUG PRODUCT DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES, PUNJAB.
      DRAP Alert NoNo I/S/03-26-22
      Action Date14 April, 2026.
      Target Audience– National Regulatory Field Force.
      – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
      – General Public
      Problem / Issue Drug Testing Laboratories of Punjab Province informed that the samples of below mentioned drug products have been declared as ‘Substandard ’.

      Therapeutic Goods (s) Affected: –

      S#Product NameBatchManufacturersRemarks
      1.Injection. Cara-Doba Each 5 ml ampoule contains: Dobutamine HCl USP eq to Dobutamine … 250 mg (Reg # 054987)26A037 & 25J016M/s Caraway Pharmaceuticals. Plot No. 12 Street No. N-3 National Industrial Zone (RCCI) Rawat. (DML # 000629)The Sample is declared as “SUB-STANDARD” on the basis of Visible Particulates in Injections and Assay Test.
      2.EPHASEF 1G Powder for Injection Each Vial contains: 1g Sterile Cephradine U.S.P. (Reg # 044343)EM073M/s E-Pharm Laboratories. A-40 S.I.T.E Super Highway North Karachi (DML # 000598)The sample is Sub-Standard with regards to Sterility test.
      3.IPROLAC Injection 30mg/mL Each 1mL contains: Ketorolac Tromethamine ….30mg ( Reg # 112065)25L048M/s Ipram International.   Plot # 26 SS-3 National Industrial Zone Rawat. (DML # 000551)The above sample is SUB-STANDARD, on the basis of Sterility test performed as per USP, and MISBRANDED on the basis of The Drugs Act, 1976, 3 (s) (iv). Product label bears, product specs: whereas monograph of exists in USP 2025, which manufacturer failed to provide is “Ketorolac specifications” from registration board. not Innovator’s Tromethamine Specifications prescribed on the approval letter of injection” label, and “Innovator’s
      4.Injection Metiver Each 1ml ampoule contains: Mecobalamin…….500mcg (Reg # 098031)25J438M/s Iqra Pharmaceuticals.   Plot No. 2, Street No. S-9, RCCI, Rawat (DML # 000899)The sample is declared as “SUB-STANDARD” on the basis of Assay Test & “ADULTERATED” as per section 3 (a) (iv) of The Drugs Act 1976 (Cyanocobalamin is Identified).
      5.MECOJIN Injection Each Ampoule contains: Mecobalamin JP ……500mcg (Reg. # 124090)25A082M/s Islam Pharmaceuticals.   7KM, Pasrur Road, Sialkot (DML # 000885)The sample is declared as “Adulterated” as per section 3 (a) (iv) of The Drugs Act 1976 (Cyanocobalamin is Identified).
      6.Sporex Injection 50ml Each Vial Contains: Sterile Powder of Ceftriaxone Sodium USP eq. to Ceftriaxone 250mg (Reg. # 055202)98101M/s Raazee Therapeutics (Pvt) Ltd. 48-Km Lahore Kasur Road Kasur. (DML # 000437)The sample is Sub-Standard with regards to Sterility.
      7.Neocobal Injection 0.5 mg/ml Each 1ml ampoule contains: Mecobalamin…….500mcg (Reg # 071447)S-2988M/s Pulse Pharmaceuticals (Pvt) Ltd.   Mozay Badoke Raiwind Road (Sua Asil Road) Lahore. (DML # 000564)The sample is declared as “sub-standard” on the basis of Assay Test & “ADULTERATED” as per section 3 (a) (iv) of The Drugs Act 1976 (Cyanocobalamin is Identified).
      8.Sidofenac Injection Each 3 ml contains Diclofenac Sodium 75 mg (Reg # 086452)DI0016M/s N.S Pharma.  Plot No. 576-577, Sunder Industrial Estate, Lahore. (DML # 000869)The sample is Sub-Standard with regards to Description (Visible Particulates In Injections).
      9.Injection Hicobal Each Ampoule contains: Mecobalamin JP ……500mcg (Reg #  032320)HT13437M/s Himont Pharmaceuticals (Pvt) Ltd.  17-Km Ferozepur Road Lahore. (DML # 000231)The sample is declared as “sub-standard” on the basis of Assay Test & “ADULTERATED” as per section 3 (a) (iv) of The Drugs Act 1976 (Cyanocobalamin is Identified).
      Risk Statement:The use of these substandard, adulterated, and misbranded injectable products poses serious health risks, including treatment failure, severe infections, hypersensitivity reactions, and potential life-threatening complications due to lack of sterility, incorrect active ingredients, or presence of particulate matter. Patients receiving critical care, antibiotics, pain management, or vitamin B12 therapy may experience worsening of their medical condition or unexpected adverse effects. Hospitalized patients, individuals receiving injectable antibiotics, cardiac support drugs, pain management injections, and patients treated for Vitamin B12 deficiency particularly those in intensive care units, emergency settings, and immunocompromised populations.
      Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

      – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

      –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk.

      –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
      Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

      -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the       Adverse Event Reporting Form or online through this link.

      -Please click here for further information on problem reporting to DRAP.
      Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

      -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

        21. Rapid Alert – SPURIOUS Nandrolone Injection 100mg/ml

        Salateen Philip Recall Alerts
        Download

        Rapid Alert

        SPURIOUS Nandrolone Injection 100mg/ml
        DRAP Alert NoNo I/S/04-26-21
        Action Date14 April, 2026
        Target Audience1. Regulatory Field Force of DRAP and Provincial Drug Control departments.
        2. Healthcare Professionals
        3. Pharmacies and medical stores
        Problem StatementDrug Testing Laboratory (DTL), Government of Punjab has reported that the sample of the following drug product has been declared as “Spurious” under Section 3(z-b)(i) of the Drugs Act, 1976.
        S#Product NameBatchManufacturerRemarks
        1Deka-Duralin Injection 100 mg/ml (Nandrolone Decanoate) Reg. No. 074187H-191Purported to be manufactured by Hansel Pharmaceuticals (Pvt.) Ltd., LahoreDeclared Spurious, API not identified; assay 0%; fails identification test
        Risk StatementUse of this spurious injectable product may result in complete therapeutic failure and may expose patients to serious health risks, particularly in conditions requiring anabolic steroid therapy.
        Action InitiatedThe Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
        Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
        Advice for ConsumersConsumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

        20. Rapid Alert – SPURIOUS DYDROGESTERONE TABLETS

        Salateen Philip Recall Alerts
        Download

        Rapid Alert

        SPURIOUS DYDROGESTERONE TABLETS
        DRAP Alert NoNo I/S/04-26-20
        Action Date14 April, 2026
        Target Audience1. Regulatory Field Force of DRAP and Provincial Drug Control departments.
        2. Healthcare Professionals
        3. Pharmacies and medical stores
        Problem StatementDrug Testing Laboratory (DTL), Government of Punjab has reported that the samples of the following drug products have been declared as “Spurious” under Section 3(z-b)(i) of the Drugs Act, 1976.
        S#Product NameBatchManufacturerRemarks
        1Dropha Tablets Each Tablet contains Dydrogesterone ……. 10mg  DRP-0011Purported to be manufactured under   M/s Himax Pharmaceutical,  Plot # 445, Korangi Industrial Area, KarachiDeclared Spurious (API not detected, assay 0%, fails identification & dissolution.
        2Efaston Tablets 10 mg (Dydrogesterone)4116Purported to be manufactured under M/s Lahore Chemical & Pharmaceutical Works (Private) Limited. 137- Ferozepur Road, Lahore (DML# 000064).Declared Spurious (API not detected, assay 0%, fails identification & dissolution.
        3Depasrone Tablets   Each Tablet contains Dydrogesterone 10mg  2648Purported to be manufactured under   M/s Alpine Laboratories, Plot A-41, S.I.T.E., KarachiDeclared Spurious (API not detected, assay 0%, fails identification & dissolution.
        Risk Statement (Dydrogesterone) is commonly prescribed for gynecological and obstetric indications. Use of a spurious product containing no active ingredient may result in therapeutic failure, leading to serious clinical consequences, including unmanaged hormonal conditions, pregnancy-related complications, and risk to maternal health.
        Action InitiatedThe Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
        Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
        Advice for ConsumersConsumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

        19. Recall Alert – WHO Recall Class-II

        Salateen Philip Recall Alerts

        Recall Alert

        Download

        Recall of Specified Batches of Curosurf (Poractant alfa) Intratracheal Suspension on Account of Microbial Contamination (Class II Recall)

        DRAP Alert NoNo II/S/04-26-19
        Action Date14 April, 2026.
        Target Audience·         National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
        ·         Healthcare Professionals-Veterinarians
        ·         Farmers/consumers
        Problem / Issue The Drug Regulatory Authority of Pakistan (DRAP) has received a Rapid Alert notification from the World Health Organization (WHO) regarding quality defect (Class II recall) of Curosurf (Poractant alfa) Intratracheal Suspension (80 mg/ml) manufactured by M/s Chiesi Farmaceutici S.p.A., Italy.
        The defect has been identified by the State Institute for Drug Control (SUKL), Czech Republic, indicating a risk of microbial contamination in certain batches of the products.
        Review of distribution data confirms that the following batches have been supplied to Pakistan:

        Therapeutic Goods (s) Affected: –

        S#Name of productBatch #Manufacturer detailsRemarks
        1.  Curosurf 1.5ml Vial (Pulmonary surfactant of Natural origin 80mg / ml – Corresponding to approx 74.0 of total phospholipids) Each vial contains: Poractant Alfa 120mg/1.5ml  1211476, 1224477, 1223964, 1204306,Manufacturer Chiesi Farmaceutici S.p.A Via Palermo, 26/A, 43122 Parma, Italy. Importer: Chiesi Pharmaceuticals (Pvt) Ltd Office No: 4, 4th Floor, Askari Corporate Towers 75/76 D-I, Main Boulevard Gulberg III, Lahore – 54000 PakistanRisk of microbial contamination
         Curosurf 3ml Vial (Pulmonary surfactant of Natural origin 80mg / ml – Corresponding to approx 74.0 of total phospholipids) Each vial contains: Poractant Alfa 240mg/3 ml  1226985
        Risk Statement:Curosurf (Poractant alfa) is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. The identified defect relates to microbial contamination, which poses a serious sterility risk due to intratracheal administration.
        Use of affected batches may result in severe infections, treatment complications, and potentially life-threatening outcomes, particularly in premature neonates who are highly vulnerable.
        The most likely affected population includes neonates admitted in Neonatal Intensive Care Units (NICUs) requiring surfactant therapy. Healthcare professionals are advised to immediately discontinue use of affected batches and ensure availability of safe alternatives.
        Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

        – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

        –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk.

        –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
        Advice for VeterinarianThis alert applies strictly to the specific batches listed above and does not apply to other batches of the same products. Veterinarians are therefore advised not to prescribe, administer, or stock these identified batches under any circumstances. In case any of the above-mentioned batches have already been administered, treated animals should be closely monitored for possible signs of infection, treatment failure, or adverse reactions, and appropriate supportive care must be provided. Any suspected adverse events or quality-related problems linked to these batches should be reported immediately to DRAP’s Pharmacovigilance Centre and to the Provincial Livestock & Dairy Development Departments. Practitioners are further advised to ensure that only alternative registered and quality-assured batches are used in veterinary practice.
        Advice for Farmers and Livestock OwnersFarmers and livestock owners are advised to immediately stop using the affected batch and isolate all remaining stock. Closely monitor treated animals for fever, swelling at the injection site, reduced appetite, or any sudden illness, and consult a veterinarian if such symptoms appear. Until animals are clinically stable, avoid selling or using milk or meat from visibly unwell animals. The affected product should be returned to the supplier or distributor according to recall instructions. Farmers are further advised to maintain proper records of batch numbers, treatment dates, and suppliers for traceability, and to ensure that only sterile, approved veterinary injections are used and stored under recommended conditions.

          18. Rapid Alert – Spurious TERBIDERM FORTE TABLET (TERBINAFINE 250 mg) & GLANTRIM OPHTHALMIC SOLUTION

          Salateen Philip Recall Alerts
          Download

          Rapid Alert

          SPURIOUS TERBIDERM FORTE TABLET (TERBINAFINE 250 mg) & GLANTRIM OPHTHALMIC SOLUTION
          DRAP Alert NoNo I/S/04-26-18
          Action Date14 April, 2026
          Target Audience1. Regulatory Field Force of DRAP and Provincial Drug Control departments.
          2. Healthcare Professionals
          3. Pharmacies and medical stores
          Problem StatementAtco Laboratories Limited, Karachi has intimated identification of suspected spurious batches of its registered products, namely Terbiderm Forte Tablet (Terbinafine 250 mg) and Glantrim Ophthalmic Solution, during market surveillance. Analytical testing conducted by the manufacturer’s Quality Control Laboratory confirmed that the Active Pharmaceutical Ingredient (API) content was not present in the tested samples. Comparative evaluation with retained samples further revealed significant discrepancies in packaging, labeling, and physical characteristics.
          Based on these findings, the following batches of these drug products have been found to be Spurious.
          S #Name of ProductBatchPurported to be Manufactured byRemarks
          1Terbiderm Forte Tablet (Terbinafine 250 mg)
          (Reg # 053367)          		HH003LM/s Atco Laboratories Limited, Karachi.
          B-18 S.I.T.E Karachi.
          (DML # 000188)            		Spurious
          2Glantrim Ophthalmic Solution
          Timolol (as Maleate) …. 0.5%w/v
          Dorzolamide (As HCl) ……2%w/v
          (Reg # 050622)          		LZ010KSpurious
          Risk StatementTerbinafine is indicated for treatment of fungal infections, while Glantrim Ophthalmic Solution is used in management of glaucoma and ocular hypertension. Laboratory findings confirm absence of active ingredients, resulting in complete therapeutic failure. Use of the mentioned batches of these drug products may lead to disease progression, treatment failure, and serious complications, particularly risk of vision-related complications in case of ophthalmic product. The public health risk is assessed as high.
          Action InitiatedThe Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.
          Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
          Advice for ConsumersConsumers should not use the mentioned batches of these drug products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

          17. Volunatry Recall. Osilex-D (Glitz Pharma)

          Salateen Philip Recall Alerts

          Recall Alert

          Download
          VOLUNTARY RECALL OF DRUG PRODUCT
          DRAP Alert NoNo II/V/03-26-14
          Action Date11 March, 2026.
          Target Audience– National Regulatory Field Force.
          – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
          – General Public
          Problem / Issue M/s Glitz Pharma, 205, Muhammadi Plaza, College Road, Rawalpindi – Pakistan (Plant: Plot No. 265, Industrial Triangle Kahuta Road, Islamabad) has informed the Drug Regulatory Authority of Pakistan (DRAP) regarding voluntary recall of the following drug product due to quality defect observed during ongoing stability studies.

          Therapeutic Goods (s) Affected: –

          S#Product NameBatchManufacturersMfg. & exp. date
          1.Osilex D
          Manufacturing Date:
          August 2025

          Expiry Date:
          July 2027.            		T22125M/s Glitz Pharma
          Plot No 265 Industrial Triangle Kahuta Road Islamabad.
          (DML # 000571)          		The firm has initiated recall of the above-mentioned batch after observing changes in physical appearance during stability studies which do not comply with approved quality specifications.
          Risk Statement:The affected batch of Osilex D Tablet exhibited changes in physical appearance during stability studies. Although no adverse event has been reported, deviation from approved quality specifications may potentially compromise product quality, safety, and efficacy. The recall is being conducted as a precautionary measure to safeguard public health and ensure regulatory compliance.
          Action InitiatedThe field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.
          Advice for Healthcare ProfessionalsDRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse
          Event Reporting Form or online through this link.  Further information of reporting problems to DRAP is available on this link.
          Advice for Pharmacies/Medical stores: –All pharmacists and chemist working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).
          Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

          -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

            16. Recall Alert (Human) – CDL Karachi declared substandard products.

            Salateen Philip Recall Alerts

            Recall Alert

            Download
            DRUG PRODUCT DECLARED SUBSTANDARD BY CENTRAL DRUGS LABORATORY KARACHI.
            DRAP Alert NoNo II/S/03-26-14
            Action Date11 March, 2026.
            Target Audience– National Regulatory Field Force.
            – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
            – General Public
            Problem / Issue Central Drugs Laboratory Karachi informed that the samples of below mentioned drug product has been declared as ‘Substandard’.

            Therapeutic Goods (s) Affected: –

            S#Product NameBatchManufacturersRemarks
            1.Santochlor ophthalmic Solution Chloramphenicol 5mg/ml (Reg # 021605)D-330M/s Sante (Pvt) Ltd. A/97 S.I.T.E Super Highway Karachi. (DML # 000702)The sample has been declared “substandard” on the basis of assay test.
            2.Ciprozat Tablet Ciprofloxacin 500mg/ per tablet (Reg # 031221)2421M/s Hizat Pharmaceutical Industry. 170 Industrial Estate Jamrud Road Peshawar. (DML # 000315)The sample has been declared “substandard” on the basis of dissolution test.
            Risk Statement:The above-mentioned batches of Santochlor Ophthalmic Solution (Chloramphenicol 5mg/ml) and Ciprozat Tablet (Ciprofloxacin 500mg) have been declared Substandard based on failure of assay and dissolution tests respectively.
            Substandard ophthalmic chloramphenicol may result in inadequate treatment of bacterial eye infections, leading to prolonged infection, worsening inflammation, or potential complications affecting vision. Substandard ciprofloxacin tablets may cause reduced therapeutic response in bacterial infections, increasing the risk of treatment failure, antimicrobial resistance, and disease progression.
            The most likely affected population includes patients suffering from eye infections and individuals being treated for bacterial infections, particularly those requiring timely and effective antibiotic therapy. Healthcare professionals are advised to discontinue use of the affected batches and ensure availability of quality-assured alternatives.
            Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

            – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

            –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk.

            –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
            Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

            -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the             Adverse Event Reporting Form or online through this link.

            -Please click here for further information on problem reporting to DRAP.
            Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

            -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

              15. Recall Alert (Veterinary) – DTLs Punjab declared substandard products.

              Salateen Philip Recall Alerts

              Recall Alert

              Download

              VETERINARY DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

              DRAP Alert NoNo I/S/03-26-15
              Action Date11 March, 2026.
              Target Audience·         National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
              ·         Healthcare Professionals-Veterinarians
              ·         Farmers/consumers
              Problem / Issue Provincial Drug Testing Laboratories, Punjab informed that the sample of below mentioned Veterinary Drug products have been declared as ‘Substandard’.

              Therapeutic Goods (s) Affected: –

              S#Product DetailsBatchManufacturer detailsRemarks
              1Injection Micrise-1% 10 ml
              Each ml contains:
              Ivermectin …. 10 mg
              (Reg # 111206)              		MR-087M/s Biorise Pharmaceuticals.
              19-Km, Lahore Road, Multan.
              (DML # 000934)              		The sample is declared as “sub-standard” on the basis of Assay Test and Chromatographic Purity Testfor related substances.
              2.Injection Wormec 1% 10 ml
              Each ml contains:
              Ivermectin …. 10 mg (Reg # 020802)
              V00845              		M/s Nawan Laboratories (Pvt) Ltd. 
              136 Sector 15 Korangi Industrial Area Karachi.
              (DML # 000442)              		The sample is declared as “Sub-Standard” on the basis of Assay Test and Chromatographic Purity Test.
              Risk Statement:The above-mentioned batches of Ivermectin Injection 1% (10 ml) have been declared Sub-Standard based on failure of Assay and Chromatographic Purity tests, indicating possible incorrect potency and/or presence of unacceptable impurities.
              Substandard veterinary ivermectin may lead to treatment failure in parasitic infections, persistent worm burden, development of drug resistance, and potential toxicity in animals. The most likely affected population includes livestock (cattle, sheep, goats) and other animals treated for internal and external parasites, particularly in farm settings where mass deworming is practiced.
              Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

              – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

              –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk.

              –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
              Advice for VeterinarianThis alert applies strictly to the specific batches listed above and does not apply to other batches of the same products. Veterinarians are therefore advised not to prescribe, administer, or stock these identified batches under any circumstances. In case any of the above-mentioned batches have already been administered, treated animals should be closely monitored for possible signs of infection, treatment failure, or adverse reactions, and appropriate supportive care must be provided. Any suspected adverse events or quality-related problems linked to these batches should be reported immediately to DRAP’s Pharmacovigilance Centre and to the Provincial Livestock & Dairy Development Departments. Practitioners are further advised to ensure that only alternative registered and quality-assured batches are used in veterinary practice.
              Advice for Farmers and Livestock OwnersFarmers and livestock owners are advised to immediately stop using the affected batch and isolate all remaining stock. Closely monitor treated animals for fever, swelling at the injection site, reduced appetite, or any sudden illness, and consult a veterinarian if such symptoms appear. Until animals are clinically stable, avoid selling or using milk or meat from visibly unwell animals. The affected product should be returned to the supplier or distributor according to recall instructions. Farmers are further advised to maintain proper records of batch numbers, treatment dates, and suppliers for traceability, and to ensure that only sterile, approved veterinary injections are used and stored under recommended conditions.